dupilumab

New treatments on the horizonEmerging therapies are showing impressive efficacy and good tolerability, according to one dermatologist.
Autoimmune drug pipeline: What health execs should watchNew drugs for RA, psoriasis, type 1 diabetes and Crohn’s disease—some recently approved and others coming down the pipeline—could have an impact on the industry.
Atopic dermatitis pipelineDrugs to treat atopic dermatitis are at the top of the FDA’s dermatology list. Biologics and PDE4 inhibitors show promise in the treatment of AD. Approval is still needed for the use of biologics to treat AD in pediatric patients.
Targeted treatments for atopic dermatitisEmerging treatments are expected to help fill the need for safer and more effective therapies for atopic dermatitis (AD). Both systemic and topical treatments are needed to provide full and complete treatment for patients with AD. Targeting the specific axis or axes that control AD may contribute to developing personalized approaches to treatment
Dupilumab demonstrates promising resultsThe systemic therapy dupilumab met primary endpoints in two phase 3 studies on adults with in inadequately controlled moderate-to-severe atopic dermatitis.
MauiDerm 2015: New drugs bring promising treatments for derm conditions
MauiDerm 2015: New drugs bring promising treatments for derm conditionsPromising new treatments for rosacea and leishmaniasis are among the highlights of a Maui Derm conference session about new drugs in dermatology.
Study identifies molecular mechanisms behind AD
Study identifies molecular mechanisms behind ADAccording to researchers, abnormalities in the skin barrier and in the immune system that characterize atopic dermatitis can be reversed by drugs that narrowly target the immune signaling proteins interleukin (IL)-4 and -13.
FDA drug approvals-November 2014FDA drug approvals, fast-track designations
Dupilumab promising in treatment of atopic dermatitisThe human monoclonal antibody dupilumab has shown promising results in treating moderate-to-severe atopic dermatitis in a series of phase 2 studies as both monotherapy and in combination with topical glucocorticoids.